AVROBIO Dirección

Dirección controles de criterios 3/4

El CEO de AVROBIO's es Erik Ostrowski , nombrado en Jan 2019, tiene una permanencia de 5.25 años. compensación anual total es $1.59M, compuesta por 31.7% salario y 68.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.065% de las acciones de la empresa, por valor de $34.70K. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 6 años, respectivamente.

Información clave

Erik Ostrowski

Chief Executive Officer (CEO)

US$1.6m

Compensación total

Porcentaje del salario del CEO	31.7%
Permanencia del CEO	5.3yrs
Participación del CEO	0.07%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Erik Ostrowski en comparación con los beneficios de AVROBIO?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$2m	US$504k	US$12m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$101m
Dec 31 2022	US$1m	US$460k	-US$106m
Sep 30 2022	n/a	n/a	-US$109m
Jun 30 2022	n/a	n/a	-US$119m
Mar 31 2022	n/a	n/a	-US$122m
Dec 31 2021	US$3m	US$439k	-US$119m
Sep 30 2021	n/a	n/a	-US$119m
Jun 30 2021	n/a	n/a	-US$123m
Mar 31 2021	n/a	n/a	-US$121m
Dec 31 2020	US$2m	US$424k	-US$120m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$95m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$3m	US$412k	-US$73m

Compensación vs. Mercado: La compensación total de Erik($USD1.59M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Erik ha sido consistente con los resultados de la empresa en el último año.

CEO

Erik Ostrowski (51 yo)

5.3yrs

Permanencia

US$1,590,892

Compensación

Mr. Erik John Ostrowski, MBA, has been Chief Financial Officer and Treasurer at AVROBIO, Inc since January 2019 and served as its Principal Accounting Officer. He serves as President and Interim Chief Exec...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Erik Ostrowski	President	5.3yrs	US$1.59m	0.065% $ 34.8k
Azadeh Golipour	Chief Technology Officer	2.3yrs	US$1.27m	0.084% $ 44.9k
Essra Ridha	Chief Medical Officer	2.6yrs	US$1.34m	0.035% $ 18.9k
Jeffrey Medin	Scientific Founder	no data	sin datos	sin datos
Steven Avruch	Chief Legal Officer & Secretary	5.3yrs	US$1.77m	0.049% $ 26.2k
Scott Gottesman	Vice President of Human Resource	2.3yrs	sin datos	sin datos
Kirsten Dupuis	Chief of Staff	no data	sin datos	sin datos

2.6yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AVRO se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ian T. Clark	Independent Director	6.3yrs	US$63.97k	0% $ 0
Phillip Donenberg	Independent Non-Employee Director	5.9yrs	US$72.97k	0.0045% $ 2.4k
Bruce Booth	Independent Chairman of the Board	8.3yrs	US$98.97k	0% $ 0
Philip Vickers	Independent Director	5.3yrs	US$73.97k	0.011% $ 5.7k
Gail Farfel	Director	3.6yrs	US$61.47k	0% $ 0
Annalisa Lisa Jenkins	Independent Director	6.1yrs	US$76.97k	0% $ 0
Christopher Paige	Independent Director	8.3yrs	US$72.97k	0.56% $ 300.5k

6.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de AVRO se considera experimentada (6 años de antigüedad promedio).

AVROBIO Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chief Business Officer notifies of intention to sell stock

Co- Founder exercised options to buy US$104k worth of stock.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

New 90-day low - US$15.85

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta